Bristol Myers rises on positive trial results for cancer and lung disease drugs

Bristol-Myers Squibb

12/10/2026 13:47

** Shares of Bristol Myers Squibb BMY.N gain 3.7% to $61.32 premarket
** A lower dose of experimental drug met late-stage trial main goal in patients with idiopathic pulmonary fibrosis, a serious lung-scarring disease
** Drugmaker says 60-mg dose of its admilparant drug, taken twice daily, showed a statistically significant benefit over placebo in preserving lung function
** Separately, its experimental radiopharmaceutical therapy significantly delayed disease-progression in patients with rare, advanced gastrointestinal and pancreatic tumors that progressed after earlier treatment
** The therapy, RYZ101, is among closely watched therapies that act like a "canonball" to kill cancer cells by delivering radioactive particles to tumorous tissue or tumor-associated cells
** As of last close, BMY up 9.6% YTD — compared with 10.3% rise in S&P 500 Health Care index .SPXHC

 (Reporting by Jayasree Prabhu)
 ((jayasree.prabhu@thomsonreuters.com))